The company said, "As of December 31, 2022, we had unrestricted cash and cash equivalents of $19.2 million. In March 2023, we amended the terms of the Hercules Term Loan Agreement and repaid $7.5 million of the outstanding principal. The minimum qualified cash balance requirement was reduced to $2.25 million and Eloxx will be required to make principal payments, plus interest, beginning in September 2023. Assuming that we initiate Phase 3 clinical trial activities in the third quarter of 2023, our expectation is that our current cash position and assuming maintaining compliance with our debt covenants, will be sufficient to fund our operations into the third quarter of 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX:
- Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
- Eloxx submits IND to FDA for ZKN-013 for treatment of RDEB
- Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Eloxx Pharmaceuticals initiates ELX-02 trial